SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2023

Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer, Marco A. Purbhoo, et al.

Poster •November 3

International Cancer Immunotherapy Conference (CICON) 2023

Counteracting Immune suppression and enhancing cytotoxic T cell activity with allogeneic invariant Natural Killer T (iNKT) cells expressing an armored CAR targeting Fibroblast Activation Protein in an advanced solid tumor model system, M. V. Dijk, et al.

Poster •September 22-23

American Thoracic Society (ATS) International Conference 2023

Administration of Novel Allogeneic iNKT Cell Infusion (agenT-797) in Patients With Severe COVID-19 Acute Respiratory Distress Syndrome (CARDS) Receiving Venovenous Extracorporeal Membrane Oxygenation (VV-ECMO) Support, T. Hammond, et al.

Poster •May 19-24

American Society of Gene and Cell Therapy (ASGCT) 2023

Development of an Allogeneic FAP-CAR iNKT Cell Therapy to Modulate the Immunosuppressive Stroma and Improve Anti-tumor Immunity Against Non-Small Cell Lung Carcinoma, S. Boi, et al.

Poster •May 16-20

American Association for Cancer Research

Phase 1 study of allogeneic invariant natural killer T cells (iNKTs), agenT-797, alone or in combination with pembrolizumab or nivolumab in patients with advanced solid tumors, B. Carneiro, et al.

Poster •April 14 - 19

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2022

Phase 1 studies of agenT-797, a novel allogeneic invariant natural killer T cell therapy, for the treatment of patients with solid tumors or multiple myeloma, D. Stevens, et al.

Poster •November 8 - 12, 2022

Invariant natural killer T (iNKT) cell therapy (agenT-797) in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19), M. Purbhoo, et al.

Poster •November 8 - 12, 2022

Development of an allogeneic FAP-CAR iNKT product to target tumor stroma and modulate the tumor microenvironment, X. Michelet, et al.

Poster •November 8 - 12, 2022

agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment, S. Pakharel, et al.

Poster •November 8 - 12, 2022

MiNK-413: A Next Generation Armored Allogenic BCMA CAR iNKT Product, E. Chantzoura1, et al.

Poster •November 8 - 12, 2022

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2021

agenT-797, a native allogeneic "off-the-shelf" iNKT cell therapy shows anti-tumor activity, B. Yigit, et al.

Poster •November 10 - 14, 2021

Identification and characterization of an allogeneic iNKT-CAR Targeting BCMA, X. Michelet, et al.

Poster •November 10 - 14, 2021

Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-based cell therapy drug product, M. Purbhoo, et al.

Poster •November 10 - 14, 2021

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2020

AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing, B. Yigit, et al.

Poster •November 11 - 14, 2020

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2019

Discovery and characterization of the first fully-human Phosphopeptide Tumor Target-specific T cell receptor, X. Michelet, et al.

Poster •November 7 - 10, 2019

Invariant natural killer T cells as an allogeneic cell therapy platform, B. Yigit, et al.

Poster •November 7 - 10, 2019